Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected ... Moving checkpoint inhibitors further up the treatment pathway into earlier adjuvant and neoadjuvant ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...